Cargando…

Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells

Targeted therapies have profoundly changed the clinical prospect in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. In particular, the anti-HER2 monoclonal antibody trastuzumab represents the gold standard for the treatment of HER2+ breast cancer patients. Its contribution in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Truffi, Marta, Colombo, Miriam, Sorrentino, Luca, Pandolfi, Laura, Mazzucchelli, Serena, Pappalardo, Francesco, Pacini, Chiara, Allevi, Raffaele, Bonizzi, Arianna, Corsi, Fabio, Prosperi, Davide
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920071/ https://www.ncbi.nlm.nih.gov/pubmed/29700387 http://dx.doi.org/10.1038/s41598-018-24968-x

Ejemplares similares

Nano-Strategies to Target Breast Cancer-Associated Fibroblasts: Rearranging the Tumor Microenvironment to Achieve Antitumor Efficacy
por: Truffi, Marta, et al.
Publicado: (2019)

Anti-MAdCAM-1-Conjugated Nanocarriers Delivering Quantum Dots Enable Specific Imaging of Inflammatory Bowel Disease
por: Truffi, Marta, et al.
Publicado: (2020)

Co-administration of H-ferritin-doxorubicin and Trastuzumab in neoadjuvant setting improves efficacy and prevents cardiotoxicity in HER2 + murine breast cancer model
por: Andreata, F., et al.
Publicado: (2020)

Combined Method to Remove Endotoxins from Protein Nanocages for Drug Delivery Applications: The Case of Human Ferritin
por: Silva, Filippo, et al.
Publicado: (2021)

Everolimus Nanoformulation in Biological Nanoparticles Increases Drug Responsiveness in Resistant and Low-Responsive Breast Cancer Cell Lines
por: Bonizzi, Arianna, et al.
Publicado: (2019)

Selective Targeting of Cancer-Associated Fibroblasts by Engineered H-Ferritin Nanocages Loaded with Navitoclax
por: Sitia, Leopoldo, et al.
Publicado: (2021)

Tumor Accumulation and Off-Target Biodistribution of an Indocyanine-Green Fluorescent Nanotracer: An Ex Vivo Study on an Orthotopic Murine Model of Breast Cancer
por: Sevieri, Marta, et al.
Publicado: (2021)

Establishment and Morphological Characterization of Patient-Derived Organoids from Breast Cancer
por: Mazzucchelli, S., et al.
Publicado: (2019)

Indocyanine Green Nanoparticles: Are They Compelling for Cancer Treatment?
por: Sevieri, Marta, et al.
Publicado: (2020)

Protein-Based Nanoparticles for the Imaging and Treatment of Solid Tumors: The Case of Ferritin Nanocages, a Narrative Review
por: Mainini, Francesco, et al.
Publicado: (2021)

Development of Tumor-Targeted Indocyanine Green-Loaded Ferritin Nanoparticles for Intraoperative Detection of Cancers
por: Sitia, Leopoldo, et al.
Publicado: (2020)

Investigation of antitumor activities of trastuzumab delivered by PLGA nanoparticles
por: Colzani, Barbara, et al.
Publicado: (2018)

HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment
por: Sitia, Leopoldo, et al.
Publicado: (2022)

Ultrastructural analysis of breast cancer patient-derived organoids
por: Signati, Lorena, et al.
Publicado: (2021)

Novel Bioengineering Strategies to Improve Bioavailability and In Vivo Circulation of H-Ferritin Nanocages by Surface Functionalization
por: Sevieri, Marta, et al.
Publicado: (2023)

In Vitro Immunoreactivity Evaluation of H-Ferritin-Based Nanodrugs
por: Sitia, Leopoldo, et al.
Publicado: (2023)

Nanometronomic treatment of 4T1 breast cancer with nanocaged doxorubicin prevents drug resistance and circumvents cardiotoxicity
por: Mazzucchelli, Serena, et al.
Publicado: (2016)

HDL Dysfunctionality: Clinical Relevance of Quality Rather Than Quantity
por: Bonizzi, Arianna, et al.
Publicado: (2021)

Impact of semi-solid formulations on skin penetration of iron oxide nanoparticles
por: Musazzi, Umberto M., et al.
Publicado: (2017)

H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer
por: Mazzucchelli, S., et al.
Publicado: (2017)

Circulating Fibroblast Activation Protein as Potential Biomarker in Patients With Inflammatory Bowel Disease
por: Corsi, Fabio, et al.
Publicado: (2021)

Bisdemethoxycurcumin (BDC)-Loaded H-Ferritin-Nanocages Mediate the Regulation of Inflammation in Alzheimer’s Disease Patients
por: Gagliardi, Stella, et al.
Publicado: (2022)

Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers
por: DiPeri, Timothy P., et al.
Publicado: (2023)

Enhanced Antitumor Effect of Trastuzumab and Duligotuzumab or Ipatasertib Combination in HER-2 Positive Gastric Cancer Cells
por: Laterza, Maria Maddalena, et al.
Publicado: (2021)

Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
por: Munzone, Elisabetta, et al.
Publicado: (2006)

CD147 knockdown improves the antitumor efficacy of trastuzumab in HER2-positive breast cancer cells
por: Xiong, Lijuan, et al.
Publicado: (2016)

Internal Quality Assurance Program for ERBB2 (HER2) Testing Improves the Selection of Breast Cancer Patients for Treatment with Trastuzumab
por: Martin, Vittoria, et al.
Publicado: (2012)

Correction: Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
por: Munzone, Elisabetta, et al.
Publicado: (2006)

Full-Length Recombinant hSP-D Binds and Inhibits SARS-CoV-2
por: Arroyo, Raquel, et al.
Publicado: (2021)

Synergistic antitumor activity by combining trastuzumab with retinoic acid in HER2 positive human breast cancer cells
por: Vanderhoeven, Fiorella, et al.
Publicado: (2018)

Does conjugation strategy matter? Cetuximab-conjugated gold nanocages for targeting triple-negative breast cancer cells
por: Avvakumova, S., et al.
Publicado: (2019)

Impact of Tuning the Surface Charge Distribution on Colloidal Iron Oxide Nanoparticle Toxicity Investigated in Caenorhabditis elegans
por: Amigoni, Loredana, et al.
Publicado: (2021)

Tumour homing and therapeutic effect of colloidal nanoparticles depend on the number of attached antibodies
por: Colombo, Miriam, et al.
Publicado: (2016)

Correction: Synergistic antitumor activity by combining trastuzumab with retinoic acid in HER2 positive human breast cancer cells
por: Vanderhoeven, Fiorella, et al.
Publicado: (2023)

Preoperative Systemic Inflammatory Biomarkers Are Independent Predictors of Disease Recurrence in ER+ HER2- Early Breast Cancer
por: Truffi, Marta, et al.
Publicado: (2021)

Multivalent Carbohydrate Nanocomposites for Tumor Microenvironment Remodeling to Enhance Antitumor Immunity
por: Hyun, Gyu Hwan, et al.
Publicado: (2023)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
por: Spanov, Baubek, et al.
Publicado: (2022)

Theranostic application of miR-429 in HER2+ breast cancer
por: Cava, Claudia, et al.
Publicado: (2020)

HER2 therapy: Molecular mechanisms of trastuzumab resistance
por: Nahta, Rita, et al.
Publicado: (2006)

Targeting HER2 in breast cancer: beyond trastuzumab
por: Winer, EP
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_tu0bga2ume8ie74jsc171ma9iq